20MED THERAPEUTICS BV

Their core work

20MED Therapeutics is a Dutch SME based in Enschede specializing in nanomedicine-based drug delivery systems for therapeutic applications. They develop nanocarriers — including nanogels, nanocapsules, and extracellular vesicle-based platforms — designed to deliver RNA therapeutics and gene therapies to targeted tissues. Their work spans neurodegenerative diseases, inherited eye disorders (Stargardt disease), and musculoskeletal conditions like osteoarthritis and intervertebral disc degeneration. They serve as a technology provider within larger research consortia, contributing specialized nano-delivery expertise to translational medicine projects.

What they specialise in

How they've shifted over time

In their earlier H2020 period (2016–2018), 20MED focused on nanocarrier platform development — nanogels, nanocapsules, nanobodies, and extracellular vesicles — primarily aimed at neurodegenerative diseases and ocular drug delivery. From 2018 onward, their work shifted toward applying these delivery platforms to specific therapeutic areas: inherited retinal diseases (Stargardt), musculoskeletal degeneration, and non-viral gene therapy. This evolution suggests a company moving from platform technology development toward disease-specific therapeutic applications.

20MED is transitioning from fundamental nanocarrier R&D toward applied gene therapy and regenerative medicine, suggesting readiness for more translational and clinical-stage collaborations.

How they like to work

20MED has never coordinated an H2020 project — they consistently join as a participant or third-party contributor, indicating a specialist role within larger consortia. With 50 unique partners across 16 countries from just 4 projects, they operate in large, multi-national training networks and research consortia. This pattern points to an organization valued for a specific technical capability (nano-delivery) that they plug into diverse research teams rather than leading them.

Despite only 4 projects, 20MED has built a broad European network of 50 partners across 16 countries, largely through participation in MSCA training networks and RIA consortia. Their network is geographically diverse with no single dominant partner country.

What sets them apart

20MED occupies a niche at the intersection of nanomedicine and therapeutic delivery — a capability that is in demand across multiple disease areas but offered by relatively few SMEs. Their versatility is demonstrated by applying nano-delivery expertise to three distinct therapeutic domains (neuro, ocular, musculoskeletal) within just four projects. For consortium builders, they offer plug-and-play nanocarrier expertise without the overhead of a large pharma partner.

Highlights from their portfolio

• B-SMART
  Largest funded project (EUR 398,125) focused on brain-targeted RNA therapeutics using multiple nanocarrier technologies — represents their core technical platform.
• CARTHAGO
  Most recent project (2020-2024) applying nanomedicine to cartilage regeneration via non-viral gene therapy, signaling their move into musculoskeletal applications.
• StarT
  Training network for a rare inherited eye disease (Stargardt), demonstrating 20MED's ability to contribute nano-delivery expertise to orphan disease research.